ATE384519T1 - Hemmer-darstellende mittel - Google Patents

Hemmer-darstellende mittel

Info

Publication number
ATE384519T1
ATE384519T1 AT04798512T AT04798512T ATE384519T1 AT E384519 T1 ATE384519 T1 AT E384519T1 AT 04798512 T AT04798512 T AT 04798512T AT 04798512 T AT04798512 T AT 04798512T AT E384519 T1 ATE384519 T1 AT E384519T1
Authority
AT
Austria
Prior art keywords
agents
inhibitant
imaging
imaging agents
mmpi
Prior art date
Application number
AT04798512T
Other languages
German (de)
English (en)
Inventor
Alan Cuthbertson
Magne Solbakken
Emma Bjurgert
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Application granted granted Critical
Publication of ATE384519T1 publication Critical patent/ATE384519T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04798512T 2003-11-14 2004-11-12 Hemmer-darstellende mittel ATE384519T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0326546.9A GB0326546D0 (en) 2003-11-14 2003-11-14 Inhibitor imaging agents

Publications (1)

Publication Number Publication Date
ATE384519T1 true ATE384519T1 (de) 2008-02-15

Family

ID=29726529

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04798512T ATE384519T1 (de) 2003-11-14 2004-11-12 Hemmer-darstellende mittel

Country Status (16)

Country Link
US (1) US20070104644A1 (enExample)
EP (1) EP1682113B1 (enExample)
JP (1) JP5043438B2 (enExample)
KR (1) KR20060118479A (enExample)
CN (1) CN1901894A (enExample)
AT (1) ATE384519T1 (enExample)
AU (1) AU2004290950A1 (enExample)
BR (1) BRPI0416528A (enExample)
CA (1) CA2545267A1 (enExample)
DE (1) DE602004011553T2 (enExample)
ES (1) ES2299884T3 (enExample)
GB (1) GB0326546D0 (enExample)
MX (1) MXPA06005355A (enExample)
NO (1) NO20062118L (enExample)
RU (1) RU2006117298A (enExample)
WO (1) WO2005049005A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2007030012A2 (en) * 2005-09-05 2007-03-15 Stichting Voor De Technische Wetenscahappen Extracellular matrix imaging
FR2891830B1 (fr) 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
GB0520527D0 (en) * 2005-10-10 2005-11-16 Ge Healthcare Ltd Automated method
ATE496881T1 (de) 2006-02-15 2011-02-15 Ge Healthcare As Kontrastmittel
EP2597083A3 (en) * 2006-03-29 2014-09-17 Novartis AG Selective hydroxamate based MMP inhibitors
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
GB0610395D0 (en) 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
WO2008075968A1 (en) * 2006-12-20 2008-06-26 Ge Healthcare As Contrast agents
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
EP2119690A1 (en) * 2008-05-14 2009-11-18 Academisch Medisch Centrum bij de Universiteit van Amsterdam Radiolabelled MMP selective compounds
JP5322527B2 (ja) * 2008-07-17 2013-10-23 浜松ホトニクス株式会社 アポトーシスの検出に適した化合物
EP2147684A1 (en) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
WO2010138720A2 (en) * 2009-05-27 2010-12-02 The Scripps Research Institute Compounds and methods for chelating metals in aqueous solutions
JP5837486B2 (ja) * 2009-07-03 2015-12-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル カチオン非依存性マンノース6−リン酸受容体を標的とする化合物
US9023318B2 (en) * 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
US8871189B2 (en) * 2011-11-30 2014-10-28 Mallinckrodt Llc MMP-targeted therapeutic and/or diagnostic nanocarriers
CN103980277B (zh) * 2014-05-27 2016-06-15 青岛大学 一种叶酸巯基化衍生物的制备方法
GB202012671D0 (en) * 2020-08-13 2020-09-30 Nrf Ithemba Labs Theranostic Compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714465A (en) * 1989-05-19 1998-02-03 Amgen Inc. Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ES2176913T3 (es) * 1997-08-08 2002-12-01 Pfizer Prod Inc Derivados de acidos arilsulfonilaminohidroxamicos.
DK1003720T3 (da) * 1997-08-08 2004-05-10 Pfizer Prod Inc Aryloxyarylsulfonylaminohydroxamsyrederivater
IL127496A0 (en) * 1997-12-19 1999-10-28 Pfizer Prod Inc The use of MMP inhibitors for the treatment of ocular angiogenesis
DK0952148T3 (da) * 1998-04-10 2004-09-20 Pfizer Prod Inc Cyclobutylaryloxyarylsulfonylaminohydroxamsyrederivater
US6677355B1 (en) * 1999-08-18 2004-01-13 Warner-Lambert Company Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors
IL138686A0 (en) * 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
DE60114022T2 (de) * 2000-05-30 2006-07-13 Board Of Governors Of Wayne State University, Detroit Matrix metalloproteinase-inhibitoren
RU2005123801A (ru) * 2003-02-10 2006-03-27 Джи-И Хелткер Лимитед. (GB) Агенты для диагностической визуализации, обладающие ингибирующей активностью в отношении матриксных металлопротеиназ (ммро)

Also Published As

Publication number Publication date
JP5043438B2 (ja) 2012-10-10
KR20060118479A (ko) 2006-11-23
MXPA06005355A (es) 2006-07-10
AU2004290950A1 (en) 2005-06-02
CN1901894A (zh) 2007-01-24
DE602004011553D1 (de) 2008-03-13
NO20062118L (no) 2006-05-11
WO2005049005A1 (en) 2005-06-02
DE602004011553T2 (de) 2009-03-26
EP1682113A1 (en) 2006-07-26
ES2299884T3 (es) 2008-06-01
CA2545267A1 (en) 2005-06-02
JP2007511494A (ja) 2007-05-10
US20070104644A1 (en) 2007-05-10
RU2006117298A (ru) 2007-12-20
EP1682113B1 (en) 2008-01-23
BRPI0416528A (pt) 2007-01-09
GB0326546D0 (en) 2003-12-17

Similar Documents

Publication Publication Date Title
ATE384519T1 (de) Hemmer-darstellende mittel
NO20072120L (no) Enzyme Inhibitor Imaging Agents
DK1472541T3 (da) Afbildningsmidler og metoder til at afbilde NAALADase og PSMA
ATE494041T1 (de) Gewebe-haltesystem für medizinische ultraschallbehandlung
BRPI0507684A (pt) agentes de contraste para formação de imagem de perfusão miocárdica
ATE349446T1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
WO2001046700A3 (en) Sodium channels as targets for amyloid beta
EP1238985A4 (en) HUMAN ANTIBODY FOR TRANSPLANTATION OF A REGION OF DETERMINATION OF COMPLEMENTARITY AGAINST GANGLIOSIDE GD3, AND DERIVATIVES THEREOF
WO2005027733A3 (en) Biological markers for diagnosing multiple sclerosis
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
DE50207866D1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
BR0014150A (pt) Diagnósticos e terapêuticos para osteoporose
FR2845267B1 (fr) Kit cutane de diagnostic de l'atopie
ITMI20011706A0 (it) Agenti di contrasto radiografici ionici e non ionici, utilizzabili per l'indagine diagnostica combinata tramite raggi-x e risonanza magnetic
IL159479A0 (en) Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
ITSV20030033A1 (it) Metodo e dispositivo per imaging diagnostico di estremita',
AU2003223033A8 (en) System for point of care diagnosis and/or analysis
NO20054049D0 (no) Fremgangsmate for diagnose og behandling.
ATE337020T1 (de) Fettsaure analoge zur diagnose von kranzarterie erkrankungen
AU2003235113A8 (en) Method of measuring neprilysin activity
ITFI20020176A1 (it) Immunoglobulina specifica per callicreina tessutale umana, formulazione immunologica comprendente detta immunoglobulina e relativo kit diagnostico per la diagnosi dell'ischemia cerebrale.
AU2002316158A1 (en) Methods and compounds for the diagnosis of inflammatory disease and identification of pharmacological agents
ITRM20020576A1 (it) Mezzi diagnostici e terapeutici per patologie correlate all'emicrania.
ITSA980007A0 (it) Procedimento di applicazione di immagini o scritte sui denti.
RU2001131293A (ru) N-(3,3-диметил-3,4-дигидроизохинолил-1)-аминокапроновая кислота, проявляющая анальгетическую активность

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties